Introduction
AOD 9604 and HGH Fragment 176-191 are both derived from the C-terminal fat-reducing domain of human growth hormone (amino acids 176-191). They share the same core sequence responsible for GH's lipolytic activity without its growth-promoting or diabetogenic effects. The key difference is that AOD 9604 includes a tyrosine modification at position 176 that enhances its metabolic stability and may improve its lipolytic potency.
Mechanism of Action Comparison
Both peptides mimic the lipolytic action of full-length GH by stimulating beta-3 adrenergic receptor-mediated lipolysis in adipose tissue. They enhance fat oxidation without affecting glucose metabolism, IGF-1 levels, or insulin sensitivity — isolating the fat-burning component of GH from its growth and metabolic effects.
HGH Fragment 176-191 is the unmodified C-terminal fragment of human growth hormone. AOD 9604 (Advanced Obesity Drug) adds a tyrosine residue at the C-terminus of the same sequence, creating a more stable analog that was specifically optimized for oral bioavailability during clinical development by Metabolic Pharmaceuticals.
Key Differences
| Feature | AOD 9604 | HGH Fragment 176-191 |
|---|---|---|
| Structural Modification | C-terminal tyrosine addition | Unmodified GH fragment |
| Stability | Enhanced (Tyr modification) | Standard peptide stability |
| Oral Bioavailability | Designed for oral delivery | Primarily injectable |
| Clinical Trial Data | Phase 2 obesity trials completed | Limited clinical data |
| IGF-1 Effects | None | None |
| Anti-lipogenic Activity | Demonstrated | Less characterized |
Research Applications
AOD 9604 has been specifically investigated for obesity treatment with completed Phase 2 clinical trials. It is also studied for cartilage repair and osteoarthritis applications (granted FDA IND status for this indication). HGH Fragment 176-191 is used in basic research on GH's lipolytic mechanisms and as a reference compound for understanding the fat-burning domain of growth hormone independent of its anabolic effects.
Which to Choose for Your Research?
For translational obesity research with clinical context, AOD 9604 offers a more characterized profile with existing trial data. For mechanistic studies of GH lipolytic domain biology, HGH Fragment 176-191 provides a cleaner, unmodified reference peptide. Both peptides serve the same fundamental purpose — isolating GH's fat-reducing activity — but AOD 9604's structural optimization makes it the more drug-like candidate.
